The 060919 GBM cell line was derived from a xenograft tumor that was sequenced as part of a GBM genome sequencing project [3] and has the next most common alteration in the RTK/AKT pathway: an inactivating PTEN mutation. This evidence concerns the gene PTEN and neoplasm.